Sol-Gel Technologies Total Long-Term Assets 2016-2024 | SLGL
Sol-Gel Technologies total long-term assets from 2016 to 2024. Total long-term assets can be defined as the sum of all assets classified as non-current
Sol-Gel Technologies Annual Total Long-Term Assets
(Millions of US $) |
| 2023 |
$4 |
| 2022 |
$4 |
| 2021 |
$12 |
| 2020 |
$6 |
| 2019 |
$6 |
| 2018 |
$4 |
| 2017 |
$5 |
| 2016 |
$3 |
| 2015 |
$2 |
Sol-Gel Technologies Quarterly Total Long-Term Assets
(Millions of US $) |
| 2024-06-30 |
$4 |
| 2024-03-31 |
$4 |
| 2023-12-31 |
$4 |
| 2023-09-30 |
$4 |
| 2023-06-30 |
$4 |
| 2023-03-31 |
$8 |
| 2022-12-31 |
$4 |
| 2022-09-30 |
$4 |
| 2022-06-30 |
$7 |
| 2022-03-31 |
$9 |
| 2021-12-31 |
$12 |
| 2021-09-30 |
$5 |
| 2021-06-30 |
$5 |
| 2021-03-31 |
$5 |
| 2020-12-31 |
$6 |
| 2020-09-30 |
$6 |
| 2020-06-30 |
$6 |
| 2020-03-31 |
$6 |
| 2019-12-31 |
$6 |
| 2019-09-30 |
$4 |
| 2019-06-30 |
$5 |
| 2019-03-31 |
$5 |
| 2018-06-30 |
$5 |
| 2018-03-31 |
$2 |
| 2017-12-31 |
|
| 2017-09-30 |
$3 |
| 2017-06-30 |
|
| 2016-12-31 |
$2 |
| 2015-12-31 |
$1 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.013B |
$0.002B |
|
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
|
